NCT06631326 2026-01-27
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
First Hospital of China Medical University
Completed
Clinical Trials
32 trialsNCT05254847 2026-01-20
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
Fudan University
Phase 2 Completed
NCT06138496 2026-01-05
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Completed
NCT05532319 2025-12-30
FRONT-1
Guangxi Medical University
Phase 2 Completed
NCT03526679 2025-12-05
LEADER
National Taiwan University Hospital
Phase 1/2 Completed
NCT02973997 2025-08-29
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Academic and Community Cancer Research United
Phase 2 Completed
NCT02678780 2025-07-24
TALENT
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT05101629 2025-07-23
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03324373 2025-04-24
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
University of Iowa
Phase 1 Completed
NCT05303090 2025-02-27
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
Fudan University
Phase 1 Completed
NCT05010668 2025-02-21
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2 Completed
NCT05003700 2024-11-05
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Completed
NCT05485896 2024-09-19
Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Completed
NCT04193553 2024-06-18
LENVAGIST
Centre Leon Berard
Phase 2 Completed
NCT06435013 2024-05-30
Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC
Sun Yat-sen University
Completed
NCT02640508 2024-05-09
Eribulin and Lenvatinib in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT03321630 2024-03-27
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
NYU Langone Health
Phase 2 Completed
NCT06253364 2024-03-13
VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy
Tongji Hospital
Completed
NCT04618367 2024-03-06
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
Sun Yat-sen University
Phase NA Completed
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT02592356 2024-03-05
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
M.D. Anderson Cancer Center
Phase NA Completed
NCT03008369 2024-02-20
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Mayo Clinic
Phase 2 Completed
NCT04642547 2023-08-01
Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
RenJi Hospital
Phase NA Completed
NCT04044313 2023-06-12
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
Sun Yat-sen University
Phase 2 Completed
NCT03841201 2023-05-12
Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03895970 2023-03-29
Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
Peking Union Medical College Hospital
Phase 2 Completed
NCT02788708 2022-09-19
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT05307926 2022-09-07
Postoperative Adjuvant Therapy of HCC Based on PD-1
Tongji Hospital
Completed
NCT02935309 2022-05-31
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04656249 2021-06-04
LENABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT02726503 2020-06-17
HOPE
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT04415567 2020-06-04
Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Completed